Table 4 The risk factors of ESKD in patients with pMN

Age (increased by 1 year)

1.002 (0.946–1.062)

0.935

Gender (male)

0.513 (0.230–1.142)

0.102

Proteinuria (increased by 1 g/24 h)

1.066 (0.924–1.229)

0.380

Serum albumin (increased by 1 g/L)

0.952 (0.844–1.074)

0.426

eGFR (increased by 1 ml/min per 1.73m²)

0.971 (0.951–0.992)

0.006

0.988 (0.957–1.020)

0.464

Anti-PLA2R antibody positivity

36.361 (0.043–30,631.182)

0.296

Anti-PLA2R antibody level (increased by 20 U/mL)

0.911 (0.746–1.112)

0.360

Anti-THSD7A antibody positivity

0.049 (0.000-)

0.904

 negative

ref

–

 1+

1.077 (0.404–2.871)

0.882

 2+

0.991 (0.387–2.535)

0.984

 3+

0.689 (0.209–2.275)

0.542

 I

ref

–

 II

3.020 (0.585–15.599)

0.187

 III

5.741 (0.514–64.088)

0.156

Global sclerosis (increased by 1%)

0.577 (0.108–3.082)

0.577

Crescent (increased by 1%)

0.530 (0.057–4.940)

0.578

Focal segmental glomerular sclerosis (increased by 1%)

0.644 (0.048–8.623)

0.740

 Grade = 0

ref

–

ref

–

 Grade = 1

0.000 (0.000–0.000)

0.985

0.000 (0.000–0.000)

0.984

 Grade = 2

0.445 (0.073–2.702)

0.379

0.460 (0.071–2.971)

0.415

 Grade = 3

61.016 (7.747–480.574)

< 0.001

25.767 (1.267–523.911)

0.035

Acute tubulointerstitial injury

6.941 (1.649–29.217)

0.008

0.897 (0.078–9.685)

0.908

 ACEI/ARBs

ref

–

 Cyclophosphamide with corticosteroids

3.002 (0.501–18.003)

0.229

 Calcineurin inhibitor w/o corticosteroids

3.479 (0.490–24.722)

0.213

No remission

14.339 (2.981–68.970)

0.001

10.161 (1.749–59.018)

0.010